当前位置：
X-MOL 学术
›
Clin. Exp. Allergy
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
A randomised, placebo‐controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)
Clinical & Experimental Allergy ( IF 6.3 ) Pub Date : 2020-10-04 , DOI: 10.1111/cea.13731 Cary D Austin 1 , Melissa Gonzalez Edick 1 , Ronald E Ferrando 1 , Margaret Solon 1 , Miriam Baca 1 , Kathryn Mesh 1 , Peter Bradding 2 , Gail M Gauvreau 3 , Kaharu Sumino 4 , J Mark FitzGerald 5 , Elliot Israel 6 , Lief Bjermer 7 , Arnaud Bourdin 8 , Joseph R Arron 1 , David F Choy 1 , Julie K Olsson 1 , Francis Abreu 1 , Monet Howard 1 , Kit Wong 1 , Fang Cai 1 , Kun Peng 1 , Wendy S Putnam 1 , Cécile T J Holweg 1 , John G Matthews 1 , Monica Kraft 9 , Prescott G Woodruff 10 ,
Clinical & Experimental Allergy ( IF 6.3 ) Pub Date : 2020-10-04 , DOI: 10.1111/cea.13731 Cary D Austin 1 , Melissa Gonzalez Edick 1 , Ronald E Ferrando 1 , Margaret Solon 1 , Miriam Baca 1 , Kathryn Mesh 1 , Peter Bradding 2 , Gail M Gauvreau 3 , Kaharu Sumino 4 , J Mark FitzGerald 5 , Elliot Israel 6 , Lief Bjermer 7 , Arnaud Bourdin 8 , Joseph R Arron 1 , David F Choy 1 , Julie K Olsson 1 , Francis Abreu 1 , Monet Howard 1 , Kit Wong 1 , Fang Cai 1 , Kun Peng 1 , Wendy S Putnam 1 , Cécile T J Holweg 1 , John G Matthews 1 , Monica Kraft 9 , Prescott G Woodruff 10 ,
Affiliation
The anti‐interleukin 13 (IL‐13) monoclonal antibody lebrikizumab improves lung function in patients with moderate‐to‐severe uncontrolled asthma, but its effects on airway inflammation and remodelling are unknown. CLAVIER was designed to assess lebrikizumab's effect on eosinophilic inflammation and remodelling.
中文翻译：
一项随机、安慰剂对照试验，评估 lebrikizumab 对不受控制的哮喘气道嗜酸性粒细胞炎症和重塑的影响 (CLAVIER)
抗白细胞介素 13 (IL-13) 单克隆抗体 lebrikizumab 可改善中度至重度未受控制的哮喘患者的肺功能，但其对气道炎症和重塑的影响尚不清楚。 CLAVIER 旨在评估 lebrikizumab 对嗜酸性粒细胞炎症和重塑的影响。
更新日期：2020-10-04
中文翻译：
一项随机、安慰剂对照试验，评估 lebrikizumab 对不受控制的哮喘气道嗜酸性粒细胞炎症和重塑的影响 (CLAVIER)
抗白细胞介素 13 (IL-13) 单克隆抗体 lebrikizumab 可改善中度至重度未受控制的哮喘患者的肺功能，但其对气道炎症和重塑的影响尚不清楚。 CLAVIER 旨在评估 lebrikizumab 对嗜酸性粒细胞炎症和重塑的影响。
京公网安备 11010802027423号